Chemomab Merges with Scipher Medicine to Advance AI-Powered Precision Treatment for Rheumatoid Arthritis

Chemomab and Scipher Medicine announce merger to develop nebokitug, a first-in-class anti-CCL24 antibody, in an AI-driven Phase 2 trial for rheumatoid arthritis. $30M new funding secured.